Testing Practices and Role of High-risk Features to Decision Making in Newly Diagnosed CLL
June 27th 2024
Leading chronic lymphocytic leukemia specialists explore strategies for selecting initial treatments, weighing the merits of fixed-duration versus continuous Bruton's tyrosine kinase inhibitor (BTKi) therapy for newly diagnosed patients.